Microchip Biotech announced that the company and its wholly-owned subsidiary Shenzhen Microchip Pharmaceutical Co., Ltd. recently received the “Notice of Acceptance” issued by the State Drug Administration for registered clinical trials of domestically produced drugs, and the clinical trial application for CS231295 tablets to treat advanced solid tumors was accepted. CS231295 tablets are small-molecule multi-target protein kinase inhibitors. Preclinical results showed that the drug showed remarkable pharmacodynamic activity, ideal pharmacokinetic characteristics, and good safety.

Zhitongcaijing · 10/17 10:09
Microchip Biotech announced that the company and its wholly-owned subsidiary Shenzhen Microchip Pharmaceutical Co., Ltd. recently received the “Notice of Acceptance” issued by the State Drug Administration for registered clinical trials of domestically produced drugs, and the clinical trial application for CS231295 tablets to treat advanced solid tumors was accepted. CS231295 tablets are small-molecule multi-target protein kinase inhibitors. Preclinical results showed that the drug showed remarkable pharmacodynamic activity, ideal pharmacokinetic characteristics, and good safety.